Treatment interruption in chronic HIV-1 infection: Does it deliver?

Current Opinion in HIV and AIDS

Volumn 2, Issue 1, 2007, Pages 26-30

  Willberg, Christian B ^a   Nixon, Douglas F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic infection; Highly active antiretroviral therapy; HIV 1; Treatment interruption

Indexed keywords

INTERLEUKIN 2;

CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; TREATMENT INTERRUPTION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VACCINATION; VIROLOGY; VIRUS LOAD; VIRUS REPLICATION;

EID: 34250616321     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3280119307     Document Type: Review

References (46)

1. Matano T, Shibata R, Siemon C, et al. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol 1998; 72:164-169.
2. Ogg GS, Jin X, Bonhoeffer S, et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol 1999; 73:797-800.
3. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-116.
4. Siliciano JD, Siliciano RF. A long-term latent reservoir for HIV-1: discovery and clinical implications. J Antimicrob Chemother 2004; 54:6-9.
5. Deeks SG, Grant RM, Wrin T, et al. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS 2003; 17:361-370.
6. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
7. Wit FW, Weverling GJ, Weel J, et al. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186:23-31.
8. Thiebaut R, Daucourt V, Mercie P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine. Clin Infect Dis 2000; 31:1482-1487.
9. Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001; 15:231-239.
10. Lisziewicz J, Rosenberg E, Lieberman J, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999; 340:1683-1684.
11. Ortiz GM, Nixon DF, Trkola A, et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest 1999; 104:R13-R18.
12. Pai NP, Lawrence J, Reingold AL, et al. Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults. Cochrane Database Syst Rev 2006; 3:CD006148. A rigorous review of trials exploring treatment interruption in chronic unsuppressed HIV-infected adults.
13. Pai NP, Tulsky JP, Lawrence J, et al. Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults. Cochrane Database Syst Rev 2005; 4:CD005482. A rigorous review of trials exploring treatment interruption in chronically infected, HIV-suppressed adults.
14. Collins S. SMART study halted due to safety concerns with significantly more AIDS events in the treatment interruption arm. HTB 2006; 7:34-35.
15. Jacobs B, Neil N, Aboulafia DM. Retrospective analysis of suspending HAART in selected patients with controlled HIV replication. AIDS Patient Care STD 2005; 19:429-438.
16. Mata RC, Viciana P, de Alarcon A, et al. Discontinuation of antiretroviral therapy in patients with chronic HIV infection: clinical, virologic, and immunologic consequences. AIDS Patient Care STD 2005; 19:550-562. This study showed that individuals who were able to continue treatment interruption had higher CD4 T-cell nadirs.
17. Krolewiecki AJ, Zala C, Vanzulli C, et al. Safe treatment interruptions in patients with nadir CD4 counts of more than 350 cells/microl: a randomized trial. J Acquir Immune Defic Syndr 2006; 41:425-429.
18. Pellegrin I, Thiebaut R, Blanco P, et al. Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and >400 CD4+ cells/microl? Impact on immunovirological parameters. J Med Virol 2005; 77:164-172. This study highlights the fact that the only immunovirological parameter that predicts the success of treatment interruption is CD4 T-cell nadir.
19. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367:1981-1989. This study looked at CD4 T-cell-guided treatment interruption, and showed that patients on CD4 T-cell-guided treatment interruption had a 2.5-fold increase in the severe morbidity rate compared with patients on continuous therapy.
20. Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006; 368:459-465.
21. Ananworanich J, Siangphoe U, Hill A, et al. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study. J Acquir Immune Defic Syndr 2005; 39:523-529.
22. Cardiello PG, Hassink E, Ananworanich J, et al. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis 2005; 40:594-600.
23. Ananworanich J, Nuesch R, Le Braz M, et al. Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 2003; 17:F33-F37.
24. Papasavvas E, Kostman JR, Mounzer K, et al. Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Med 2004; 1:e64.
25. Silva WP, Santos DE, Leal E, et al. Reactivation of ancestral strains of HIV-1 in the gp120 V3 env region in patients failing antiretroviral therapy and subjected to structured treatment interruption. Virology 2006; 354:35-47.
26. Delaugerre C, Peytavin G, Dominguez S, et al. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097). J Med Virol 2005; 77:345-350.
27. Ghosn J, Wirden M, Ktorza N, et al. No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients. AIDS 2005; 19:1643-1647.
28. Katlama C, Dominguez S, Gourlain K, et al. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS 2004; 18:217-226.
29. Lawrence J, Mayers DL, Hullsiek KH, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003; 349:837-846.
30. Ruiz L, Ribera E, Bonjoch A, et al. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study. J Infect Dis 2003; 188:977-985.
31. Harrer T, Harrer E, Kalams SA, et al. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection: breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol 1996; 156:2616-2623.
32. Karlsson AC, Younger SR, Martin JN, et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS 2004; 18:981-989.
33. Papasavvas E, Kostman JR, Thiel B, et al. HIV-1-specific CD4+ T cell responses in chronically HIV-1 infected blippers on antiretroviral therapy in relation to viral replication following treatment interruption. J Clin Immunol 2006; 26:40-54.
34. Choi JY, Song YG, Park YS, et al. HIV-specific cellular immune responses are stimulated by structured treatment interruption in chronically HIV-1 infected Koreans. Yonsei Med J 2006; 47:282-286.
35. Libois A, Lopez A, Garcia F, et al. Dynamics of T cells subsets and lymphoproliferative responses during structured treatment interruption cycles and after definitive interruption of HAART in early chronic HIV type-1-infected patients. AIDS Res Hum Retroviruses 2006; 22:657-666. This study showed that the exposure and level of antigen could influence T-cell maturation, potentially overwhelming the immune response.
36. 3. J Acquir Immune Defic Syndr 2004; 36:791-799.
37. Altfeld M, van Lunzen J, Frahm N, et al. Expansion of preexisting, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection. J Clin Invest 2002; 109:837-843.
38. Mussini C, Pinti M, Bugarini R, et al. Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study. AIDS 2005; 19:1627-1633.
39. Nuesch R, Ananworanich J, Sirivichayakul S, et al. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Clin Infect Dis 2005; 40:728-734.
40. 3 after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102. J Acquir Immune Defic Syndr 2006; 42:140-148.
41. Levy Y, Durier C, Lascaux AS, et al. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS 2006; 20:405-413.
42. Ide F, Nakamura T, Tomizawa M, et al. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial. J Med Virol 2006; 78:711-718.
43. Garcia F, Lejeune M, Climent N, et al. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis 2005; 191:1680-1685.
44. Trkola A, Kuster H, Rusert P, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11:615-622.
45. Abadi J, Sprecher E, Rosenberg MG, et al. Partial treatment interruption of protease inhibitor-based highly active antiretroviral therapy regimens in HIV-infected children. J Acquir Immune Defic Syndr 2006; 41:298-303. This study describes the effects of therapy simplification by partial therapy interruption in children.
46. Legrand FA, Abadi J, Jordan KA, et al. Partial treatment interruption of protease inhibitors augments HIV-specific immune responses in vertically infected pediatric patients. AIDS 2005; 19:1575-1585. This study reports that HIV-specific cellular responses are increased in children who received partial treatment interruption.